Trispecific antibody CS-2009 has in vivo activity

Nov. 13, 2024

Cstone Pharmaceuticals Co. Ltd. presented preclinical data of CS-2009, a trispecific antibody targeting PD-1, CTLA-4 and VEGF-A, for cancer immunotherapy.

BioWorld Science Conferences Society for Immunotherapy of Cancer Cancer Antibody Immuno-oncology

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for January 31, 2025

Vilastobart set apart? Xilio phase II combo performs in CRC

BioWorld

“The [colorectal cancer field is moving, and thankfully it’s moving quickly,” said Marwan Fakih, gastrointestinal specialist at City of Hope, speaking about...

Novo weight-loss data roll out; Veru ‘leans’ in

BioWorld

As investors look ahead to data shortly from Veru Inc. with enobosarm, the weight-loss space remains hot, with Novo Nordisk A/S reporting favorable top-line...

Appointments and advancements for Jan. 29, 2025

BioWorld

New hires and promotions in the biopharma industry, including: Allogene, Alumis, Beximco, Clarametyx, Commit, Concerto, OS Therapies, Precision, Roche, Scholar Rock.

PFA update: Abbott to launch in EU, J&J hold indefinite

BioWorld MedTech

A pair of investor calls on Jan. 22 added clarity to the rapidly evolving cardiac ablation market with Abbott Laboratories and Johnson & Johnson providing updates...